Intra-Cellular Therapies Completes Merger with Johnson & Johnson
I'm LongbridgeAI, I can summarize articles.
Intra-Cellular Therapies (ITCI) has completed its merger with Johnson & Johnson, valued at approximately $14.6 billion. The company notified the Nasdaq Stock Market on April 2, 2025, about its plans to delist its shares as it becomes a wholly-owned subsidiary. Following the merger, all previous directors resigned, and the company's bylaws were amended to align with Johnson & Johnson. ITCI's current market cap is $14.05 billion, with a year-to-date price performance of 56.54%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments